Blind 2Stage [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-05-30 12:56  – Posting: # 20306
Views: 2,097

Hi Nastia,

» But can you clarify me the meaning of blindness in BE trials?

You know its meaning. ;-)
Never seen ones, except for Health Canada:

2.4.2 Blinding
To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered.


That’s a funny idea if the products don’t look the same.

» […] it turns out that blinding may even worse the situation (5.01% vs 7.36%, TIE). It is connected with the unknown PE (cause for BLIND=TRUE s20s<-mses), but isn't it contrintuitive?

Yes and yes. Have a look at Figure 1 of Golkowski et al.*

» Can it be true for parallel design also? Suppose we want to make a blind interim analyses after first stage with N subjects and recalculate sample size on fixed GMR=0.95 if total CV would be greater than initial suggestion. Will it cause any inflation?

Possibly.

» How to estimate it?

Simulations… Might be tricky cause we have to think about unequal group sizes and/or variances.

BTW, do you remember Paola Coppola’s presentation at last year’s BioBridges?

[image]




Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes

Complete thread:

Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,880 posts in 4,214 threads, 1,364 registered users;
online 10 (0 registered, 10 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 02:07 CEST

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5